Nikita Shah Biography and Net Worth

Nikita serves as Executive Vice President, Chief Human Resources Officer and Strategic Planning Officer. In this role, she is responsible for overseeing Amneal’s Human Resources, Internal Communications and Corporate Social Responsibility functions. She also partners with the Co-CEOs to lead the creation and execution of the company’s long-term Corporate Strategy. Nikita joined Amneal in January 2014 as Senior Vice President, Human Resources & Corporate Affairs, and has served roles of increasing responsibility as a member of the company’s executive leadership team. Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, then a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held leadership roles at AT&T and Deloitte. She holds a master’s degree in accounting and auditing from Gujarat University, India and is a certified public accountant.

How old is Nikita Shah?: Ms. Shah is currently 45 years old. There are 5 older executives and no younger executives at Amneal Pharmaceuticals. The oldest executive at Amneal Pharmaceuticals is Mr. Andrew S. Boyer, Executive VP & Chief Commercial Officer of Generics, who is 58 years old. Learn More on Nikita Shah's age.
How do I contact Nikita Shah?: The corporate mailing address for Ms. Shah and other Amneal Pharmaceuticals executives is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. Amneal Pharmaceuticals can also be reached via phone at 908-947-3120 and via email at [email protected]. Learn More on Nikita Shah's contact information.
Has Nikita Shah been buying or selling shares of Amneal Pharmaceuticals?: Nikita Shah has not been actively trading shares of Amneal Pharmaceuticals during the last quarter. Most recently, Nikita Shah sold 2,000 shares of the business's stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $3.95, for a transaction totalling $7,900.00. Learn More on Nikita Shah's trading history.
Who are Amneal Pharmaceuticals' active insiders?: Amneal Pharmaceuticals' insider roster includes Andrew Boyer (EVP, Chief Commercial Officer – Generics), Chirag Patel (Co-Founder, Co-CEO, President & Director), Gautam Patel (Director), Nikita Shah (EVP), and Joseph Todisco (EVP). Learn More on Amneal Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amneal Pharmaceuticals?: During the last year, insiders at the sold shares 1 times. They sold a total of 43,657 shares worth more than $375,886.77. The most recent insider tranaction occured on November, 15th when SVP Jason B Daly sold 43,657 shares worth more than $375,886.77. Insiders at Amneal Pharmaceuticals own 26.6% of the company. Learn More about insider trades at Amneal Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Nikita Shah Insider Trading History at Amneal Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/15/2021	Sell	2,000	$3.95	$7,900.00
8/21/2018	Sell	50,000	$23.46	$1,173,000.00

Nikita Shah Buying and Selling Activity at Amneal Pharmaceuticals

Amneal Pharmaceuticals Company Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Today's Range

Now: $7.78

$7.57

$7.86

50 Day Range

MA: $8.42

$7.69

$9.25

2 Week Range

Now: $7.78

$5.01

$9.48

Volume

1,657,823 shs

Average Volume

1,382,215 shs

Market Capitalization

$2.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>